Project description:Previous studies discovered that MTDH frequently amplifies and overexpresses in breast cancer in human patients and is strongly associated with higher metastasis and treatment failure and thereby leads to poor prognosis. In mouse mammary tumor models, knockout of Mtdh substantially reduces tumor incidence and suppresess metastasis. Furthermore, Mtdh interact with Snd1 and the interaction appears essential for its tumor promoting function. To develop novel therapeutics targeting Mtdh function, small molecular compound to disrupt the Mtdh-Snd1 interaction was identified by high throughput screen. To further elucidate the mechanism of MTDH targeting caused anti-tumor activity and to confirm the action mode of the small molecular compound C26A6 as a Mtdh-Snd1 disruptor, transcriptome changes in mouse mammary tumors following treatments of C26A6 and acute induction of Mtdh knockout by Tamoxifen treatment were investigated using next generation sequencing.

2021-09-07 | GSE159764 | GEO

UBE2S targets RPL26 for ubiquitination and degradation to promote non-small cell lung cancer progression via regulating c-Myc.

Project description: Not available

| S-EPMC10492117 | biostudies-literature

Small-Molecule Ferroptotic Agents with Potential to Selectively Target Cancer Stem Cells.

Project description: Not available

| S-EPMC6459861 | biostudies-literature

Triptolide targets PPP2CA/ITGA5 axis to suppress lactate-driven ovarian cancer progression.

Project description: Not available

| S-EPMC12326723 | biostudies-literature